The Federal Trade Commission (FTC) filed a lawsuit on Friday to block Covetrus's proposed $3.5 billion acquisition of MWI Veterinary Supply, a unit of Cencora. The regulator argues that combining the two largest distributors of veterinary drugs and supplies would harm competition in the market.
Why the FTC is stepping in
Veterinary clinics rely on distributors to deliver everything from prescription medications to routine supplies like syringes and bandages. These distributors act as middlemen between manufacturers and clinics, ensuring that products arrive quickly and reliably.
The FTC says that if Covetrus and MWI merge, clinics and large corporate buyers would have fewer realistic alternatives. That concentration could lead to higher prices or worse service over time, as the merged company would have less incentive to compete aggressively.
Under modern antitrust standards, the FTC labeled the deal “presumptively unlawful.” That means when a merger significantly concentrates a market, regulators can start from the assumption that it violates competition laws, unless the companies can prove otherwise.
Covetrus pushes back
Covetrus argues that veterinary clinics still have plenty of options, pointing to other distributors and direct purchasing channels. The company says the deal would actually improve efficiency and service for its customers.
This is a common defense in antitrust cases: the merging parties argue that the market is broader than regulators claim, and that customers have alternatives. The FTC, however, believes that the two companies are the dominant players in a market that is already highly concentrated.
What this means for investors
For everyday investors, this lawsuit is a reminder that regulatory risk is a real factor in any major merger. When a deal is challenged, it can be delayed for months or even blocked entirely, which can affect the stock prices of both the acquirer and the target.
If the FTC succeeds, Covetrus would lose access to MWI's business, and Cencora would have to find another buyer or keep MWI. That uncertainty can weigh on shares of both companies until the case is resolved.
For those who own shares in either company, it's worth watching how the legal battle unfolds. A quick settlement or a court ruling in favor of the merger could boost the deal's chances, while a prolonged fight could lead to the deal falling apart.
This case also fits into a broader trend of regulators taking a tougher stance on mergers, especially in industries where a few players dominate. Similar scrutiny has been seen in other sectors, such as when private equity firms paused a major payments deal amid regulatory concerns.
What happens next
The FTC's lawsuit will now go through the legal process. The companies could choose to fight in court, negotiate a settlement, or abandon the deal altogether. The outcome will depend on how the judge weighs the competitive concerns against the companies' arguments.
For now, veterinary clinics and pet owners may not see immediate changes. But if the merger is blocked, it would preserve the current competitive landscape, which could help keep prices in check.
Investors should also keep an eye on other regulatory actions, as they can signal how the government views consolidation in various industries. For example, unitholders recently rejected a major real estate breakup, showing that shareholders also play a role in deal outcomes.
Ultimately, this case is about more than just two companies. It's about whether the market for veterinary supplies remains competitive, and that has implications for the cost of pet care for millions of Americans.
